ADCK1, DAPK3, DMPK STK17A and VRK2 were found to be similarly amplified in other cancers including prostate adenocarcinoma, uterine carcinosarcoma and pancreatic adenocarcinoma. Here, VRK2 is linked to prostate adenocarcinoma.